We conclude that FEN1 is an attractive anti-cancer target in epithelial ovarian cancers, and pharmacological targeting of the nuclease with more advanced small molecule inhibitors is a promising avenue for cancer therapy. Here, FEN1 is linked to ovarian carcinoma.